ALEXIS Biochemicals: Polyclonal Antibody to CYLD (human) (AF888)

ALX-210-910

Revised 29-Feb-08

Polyclonal Antibody to CYLD (human) (AF888)
SYNONYMS	anti-Cylindromatosis Tumor Suppressor Protein (human) PAb (AF888)
PRODUCT LINE	Signal Transduction
PRODUCT CATEGORY	NF-kB Pathway Other Products

Ordering Information

Product Numbers:	Format:	Size:	Unit Price:	Quantity:	Add To Cart
ALX-210-910-C050		50 µg	195.00 USD

Product Specification

SPECIES CROSSREACTIVITY:	Human
SOURCE/HOST:	From rabbit.
CONCENTRATION:	0.45mg/ml
PURITY DETAIL:	Epitope-affinity purified.
FORMULATION:	Liquid. In PBS containing 1% BSA and 0.02% sodium azide.
IMMUNOGEN:	Synthetic peptide corresponding to aa 56-70 (G⁵⁶HSRIPSAKGKKNQI⁷⁰) of human CYLD (cylindromatosis tumor suppressor protein).
SPECIFICITY:	Recognizes human CYLD. Detects a band of ~120kDa by Western blot.
APPLICATION:	Immunocytochemistry (on transfected cells; 1:200) Western Blot (on transfected cells; 1:3'000). Optimal conditions must be determined individually for each application.
SHIPPING:	SHIPPED ON BLUE ICE
SHORT TERM STORAGE:	+4°C
LONG TERM STORAGE:	-20°C
USE/STABILITY:	Stable for at least 1 year after receipt when stored at -20°C.
HANDLING:	Avoid freeze/thaw cycles.

Product Images

Please click on thumbnails to enlarge.

Product Specific Literature References

The tumor suppressor CYLD Acts as a Negative Regulator for Toll-like Receptor 2 Signaling via Negative Cross-talk with TRAF6 and TRAF7: H. Yoshida, et al.; J. Biol. Chem. 280, 41111 (2005) Abstract; Full Text

General Information

Cylindromas are benign adnexal skin tumors caused by germ line mutations in the CYLD gene. In most cases the second wild type allele is lost in tumor tissue suggesting that CYLD functions as tumor-suppressor. CYLD is a protein of 956 amino acids harboring a functional deubiquitinating domain at the C-terminal end. CYLD was shown to interact with TRAF2, NEMO and TRIP (Trompouki et al.; Brummelkamp et al.; Kovalenko et al.; Regamey et al.). Furthermore, CYLD is a negative regulator of NF-κB activation mediated by TNF family members and IL-1β. Downregulation of NF-κB activity depends on the deubiquitinating activity of CYLD which removes lysine-63 linked ubiquitin chains from target proteins. These findings indicate that cylindromas arise through constitutive NF-κB activation leading to hyperproliferation and tumor growth.

MANUFACTURER

Manufactured by Apotech Corporation.

General Literature References

CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members: E. Trompouki, et al.; Nature 424, 793 (2003) Abstract
Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-kappaB: T.R. Brummelkamp, et al.; Nature 424, 797 (2003) Abstract
The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination: A. Kovalenko, et al.; Nature 424, 801 (2003) Abstract
The tumor suppressor CYLD interacts with TRIP and regulates negatively nuclear factor kappaB activation by tumor necrosis factor: A. Regamey, et al.; J. Exp. Med. 198, 1959 (2003) Abstract

Further Categories Containing This Product:

Deubiquitination Other Products • Polyclonal Antibodies • Tumor Suppressors / Related Products

another CS2 website

Online Product Ordering

Clipboard [0]

Your items will be kept only for the duration of your visit.